Fact CheckerSign in

NCT07525349Not yet recruiting

Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer

The Immune-Stromal Landscape of Muscle-Invasive Urothelial Bladder Carcinoma: A Morphological Histopathological Study

Source: ClinicalTrials.gov · Last updated 13 Apr 2026

Brief summary (registry, in English)

Bladder cancer is a significant global health issue. When the cancer spreads into the muscle layer of the bladder (muscle-invasive bladder cancer), a common treatment is the surgical removal of the bladder (radical cystectomy). However, even after surgery, it can be difficult for doctors to accurately predict how an individual patient's disease will progress using standard staging methods. This retrospective observational study aims to find better ways to predict patient outcomes by examining the tumor microenvironment, which is the environment immediately surrounding the cancer cells. Specifically, researchers are looking at the relationship between the tumor cells, the surrounding supportive tissue (the stroma), and the patient's natural immune cells. The study will review existing medical records and archived tumor tissue samples from at least 100 patients who underwent radical cystectomy at the South Egypt Cancer Institute between 2018 and 2024. Under a microscope, researchers will assess three main features: * Tumor-Stroma Ratio (TSR): The amount of tumor tissue compared to the surrounding supportive tissue. * Tumor-Infiltrating Lymphocytes (TILs): The number of immune cells that have moved into the tumor to try and fight it. * Tertiary Lymphoid Structures (TLS): Organized clusters of immune cells that form near the tumor. By analyzing these features, the researchers hope to determine if specific patterns of immune and supportive cells are linked to better or worse survival rates, such as Overall Survival and Disease-Free Survival. Understanding this immune-stromal landscape could lead to more personalized risk assessments and better treatment plans for future bladder cancer patients.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
7 Apr 2026
Start date
May 2026
Primary completion date
May 2027
Lead sponsor
Assiut University
NCT number
NCT07525349

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From May 2026 to the primary completion date, May 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who received neoadjuvant chemotherapy or radiotherapy.
  • History of prior or concurrent malignancy.

Other

  • Cases with non-urothelial histological subtypes (e.g., pure squamous cell carcinoma).
  • Cases with missing or inaccessible clinical follow-up data.

Who the study is looking for

  • Patients who underwent radical cystectomy for muscle invasive urothelial carcinoma.
  • Treated at the South Egypt Cancer Institute (SECI) between 2018 and 2024.

Sex: All

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.